Clinical trial reveals that Accro Skin Drug reduces 85% of psoriasis scales in its phase II stage.
Accro Bioscience to Present Phase II Clinical Study Results for AC-201 at EADV Congress
Accro Bioscience, a clinical-stage biotech company, will be presenting the results from a Phase II clinical study at the upcoming European Academy of Dermatology & Venereology (EADV) Congress. The presentation, titled "Efficacy and Safety of a Selective Oral TYK2/JAK1 Inhibitor, AC-201, in Patients with Plaque Psoriasis: A Phase II, Randomized, Double-blinded, Placebo-Controlled Trial," will take place during the Late Breaking Sessions at the Congress.
The study focuses on AC-201, an oral, selective TYK2/JAK1 Inhibitor, which is being used in the treatment of moderate-to-severe plaque psoriasis. The abstract ID for the presentation is LBA-5, and the session title is D3T01.4F.
The presentation will take place in the Paris Nord room on Friday, 19 September, from 17:15 to 17:30. The EADV Congress is being held from 17-20 September in Paris, France.
Accro Bioscience is a company that specialises in the molecular mechanisms of regulated cell death and related pathogenesis in human diseases. However, the search results do not provide information about the name of the leader or chief medical officer of Accro Bioscience involved in the Phase II clinical studies evaluating AC-201.
The EADV Congress is a significant event in the field of dermatology and venereology, and the presentation of the Phase II clinical study results for AC-201 in moderate-to-severe plaque psoriasis will be an oral presentation. This presentation is sure to generate interest and provide valuable insights into the potential of AC-201 as a treatment for plaque psoriasis.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
